Savara Inc. (NASDAQ:SVRA) Receives Average Rating of “Moderate Buy” from Analysts

Savara Inc. (NASDAQ:SVRA) has received a consensus rating of “Moderate Buy” from the eight ratings firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $10.1429.

A number of brokerages have recently commented on SVRA. Oppenheimer initiated coverage on Savara in a report on Friday, April 24th. They issued an “outperform” rating and a $11.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Savara in a report on Tuesday, April 21st. HC Wainwright reiterated a “buy” rating on shares of Savara in a report on Monday, March 16th. William Blair set a $10.00 target price on Savara in a research report on Monday, March 16th. Finally, Wall Street Zen upgraded Savara from a “sell” rating to a “hold” rating in a research note on Saturday, June 13th.

Institutional Trading of Savara

Hedge funds and other institutional investors have recently made changes to their positions in the business. Prudential Financial Inc. bought a new stake in shares of Savara in the second quarter worth $30,000. BNP Paribas Financial Markets grew its position in Savara by 52.3% in the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock valued at $31,000 after purchasing an additional 4,626 shares in the last quarter. Brevan Howard Capital Management LP bought a new position in Savara in the second quarter valued at $33,000. Russell Investments Group Ltd. increased its stake in Savara by 930.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock valued at $37,000 after buying an additional 9,463 shares during the last quarter. Finally, CIBC Bancorp USA Inc. acquired a new stake in Savara in the 3rd quarter valued at $44,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Savara Stock Performance

Shares of NASDAQ:SVRA opened at $6.22 on Friday. The firm has a market cap of $1.27 billion, a price-to-earnings ratio of -11.11 and a beta of 0.24. Savara has a 12 month low of $2.10 and a 12 month high of $7.01. The company’s fifty day simple moving average is $5.32 and its 200 day simple moving average is $5.56. The company has a quick ratio of 13.47, a current ratio of 13.47 and a debt-to-equity ratio of 0.17.

Savara (NASDAQ:SVRA) last announced its earnings results on Tuesday, May 12th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). As a group, research analysts forecast that Savara will post -0.57 EPS for the current fiscal year.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.